Laurus Labs Ltd - 540222 - Q3 Financial Results For FY 2022
Q3 Financial Results for FY 202227-01-2022
27-01-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
LAURUS LABS LTD. Q3 & 9M FY22 RESULTS CONFERENCE CALL ON FRIDAY, JANUARY 28, 2022 AT 11:00 AM IST21-01-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication21-01-2022
Laurus Labs Ltd - 540222 - Board Meeting Intimation for Consideration Of The Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2021
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2022 ,inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 202119-01-2022
Laurus Labs Ltd - 540222 - Shareholding for the Period Ended December 31, 2021
Laurus Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here12-01-2022
Laurus Labs Ltd - 540222 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 and based on the certificates received from KFin Technologies Private Limited (Registrar and Share Transfer Agent), we hereby confirm that no requests received from depository participants for dematerialization of securities during the quarter ended December 31, 202 1. This is for your information and records.10-01-2022
Laurus Labs Ltd - 540222 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0770 Name of the Signatory :- CS Venkateswar Reddy GDesignation :- Company Secretary and Compliance Officer10-01-2022
First up: Jefferies puts buy rating on Gland, Laurus Labs
Jefferies has initiated coverage on Gland Pharma and Laurus Labs with buy ratings as it believes that Indian contract development and manufacturing companies (CDMO) are seeing a significant order flow improvement along with strong growth visibility.06-01-2022
Laurus Labs Ltd - 540222 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of the Company shall remain closed from January 01, 2022 till 48 hours after the declaration of un-audited financial results for the quarter and nine months ended December 31, 2021. The date of Board Meeting of the Company for consideration and approval of the un-audited financial results for the quarter and nine months ended December 31, 2021 will be intimated later.30-12-2021
Laurus Labs is Anand Rathi's top stock pick for the month. Check target price
Laurus Labs shares have been under pressure since quiet some time but at this juncture its trading near its crucial support, highlighted Anand Rathi24-12-2021